Akeso breaks through the ceiling again
Head-to-Head: Statistically Significant Positive Overall Survival (OS)
Time：
2026-06-01 08:54
Author：
xieyijun
It's Time: China's Innovative Drugs Need a Home Ground of Their Own
July 22-24 – See you in Shanghai!
Time：
2026-05-31 17:26
Author：
xieyijun
CPIC 2026: From Networking to Deal-Making
Time：
2026-05-31 09:13
Author：
xieyijun
At a Turning Point: Witnessing the Birth of China’s Answer to JPM
Time：
2026-05-30 16:47
Author：
xieyijun
CPIC 2026丨Global Session on Small Nucleic Acid Drug Innovation – First Speakers Revealed
Time：
2026-05-30 15:11
Author：
xieyijun
Time：
2026-05-30 14:53
Author：
xieyijun
Time：
2026-05-30 10:31
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务